A Predictive Model of Therapeutic Monoclonal Antibody Dynamics and Regulation by the Neonatal Fc Receptor (FcRn)
暂无分享,去创建一个
[1] Kåre Rygaard,et al. Quantitation and Gompertzian analysis of tumor growth , 1997, Breast Cancer Research and Treatment.
[2] E. Choi,et al. The MHC Class I-Like IgG Receptor Controls Perinatal IgG Transport, IgG Homeostasis, and Fate of IgG-Fc-Coupled Drugs1 , 2003, The Journal of Immunology.
[3] Y. Yarden,et al. The basic biology of HER 2 , 2005 .
[4] P. Bjorkman,et al. High-affinity binding of the neonatal Fc receptor to its IgG ligand requires receptor immobilization. , 1997, Biochemistry.
[5] L E Williams,et al. Numerical selection of optimal tumor imaging agents with application to engineered antibodies. , 2001, Cancer biotherapy & radiopharmaceuticals.
[6] R K Jain,et al. Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. , 1990, Journal of the National Cancer Institute.
[7] M. Brandon,et al. Importance of the liver in immunoglobulin catabolism. , 1982, Research in veterinary science.
[8] R. Begent,et al. Mathematical model of antibody targeting: important parameters defined using clinical data. , 2001, Physics in medicine and biology.
[9] Robert L. Dedrick,et al. Animal scale-up , 1973, Journal of Pharmacokinetics and Biopharmaceutics.
[10] M. Simionescu,et al. Functional expression of the MHC class I-related receptor, FcRn, in endothelial cells of mice. , 1998, International immunology.
[11] B. Haraldsson,et al. Transport of macromolecules across microvascular walls: the two-pore theory. , 1994, Physiological reviews.
[12] M. Delp,et al. Physiological Parameter Values for Physiologically Based Pharmacokinetic Models , 1997, Toxicology and industrial health.
[13] T. Waldmann,et al. The mechanism of intestinal uptake and transcellular transport of IgG in the neonatal rat. , 1972, Gut.
[14] Ivan Nestorov,et al. Whole Body Pharmacokinetic Models , 2003, Clinical pharmacokinetics.
[15] R K Jain,et al. Physiologically based pharmacokinetic modeling: principles and applications. , 1983, Journal of pharmaceutical sciences.
[16] E. Ward,et al. Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice. , 1996, European journal of immunology.
[17] Jin‐Kyoo Kim,et al. Mapping the site on human IgG for binding of the MHC class I‐related receptor, FcRn , 1999, European journal of immunology.
[18] J. Burke,et al. A relative weighting method for estimating parameters and variances in multiple data sets , 1996 .
[19] C. Anderson,et al. The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[20] Pamela J. Bjorkman,et al. Crystal structure of the complex of rat neonatal Fc receptor with Fc , 1994, Nature.
[21] E. Ward,et al. Transcytosis and catabolism of antibody , 2002, Immunologic research.
[22] D. Goldenberg,et al. Rapid Blood Clearance of Immunoglobulin G 2 a and Immunoglobulin G 2 b in Nude Mice 1 , 2006 .
[23] D. Hicklin,et al. Monoclonal antibody therapeutics and apoptosis , 2003, Oncogene.
[24] Raimund J. Ober,et al. Visualizing the Site and Dynamics of IgG Salvage by the MHC Class I-Related Receptor, FcRn1 , 2004, The Journal of Immunology.
[25] Yinghui Zhou,et al. Choice of designs and doses for early phase trials , 2004, Fundamental & clinical pharmacology.
[26] M. V. van Zwieten,et al. Serum immunoglobulins in nude mice and their heterozygous littermates during ageing. , 1980, Immunology.
[27] Patrick Poulin,et al. Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection. , 2003, Toxicology letters.
[28] M. Neumaier,et al. Kinetic and affinity constants of epitope specific anti-carcinoembryonic antigen (CEA) monoclonal antibodies for CEA and engineered CEA domain constructs. , 1998, Immunotechnology : an international journal of immunological engineering.
[29] R. Paxton,et al. Tumor uptake as a function of tumor mass: a mathematic model. , 1988, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[30] Esther Jacobowitz Israel,et al. Requirement for a beta 2-microglobulin-associated Fc receptor for acquisition of maternal IgG by fetal and neonatal mice. , 1995, Journal of immunology.
[31] H. Akaike. A new look at the statistical model identification , 1974 .
[32] C. White,et al. Rituximab: expanding role in therapy for lymphomas and autoimmune diseases. , 2004, Annual review of medicine.
[33] J N Weinstein,et al. Pharmacokinetics of monoclonal immunoglobulin G1, F(ab')2, and Fab' in mice. , 1986, Cancer research.
[34] F. W. R. BRAMBELL,et al. A Theoretical Model of γ-Globulin Catabolism , 1964, Nature.
[35] R K Jain,et al. Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. , 1994, Cancer research.
[36] D. Schoenfeld,et al. Increased clearance of IgG in mice that lack β2‐microglobulin: possible protective role of FcRn , 1996, Immunology.
[37] S. Rafii,et al. Inhibition of both paracrine and autocrine VEGF/ VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[38] R. Hansen,et al. Pharmacokinetic/pharmacodynamic modeling of the effects of intravenous immunoglobulin on the disposition of antiplatelet antibodies in a rat model of immune thrombocytopenia. , 2003, Journal of pharmaceutical sciences.
[39] J. Fahey,et al. FACTORS CONTROLLING SERUM γ-GLOBULIN CONCENTRATION , 1963, The Journal of experimental medicine.
[40] N. Simister. Placental transport of immunoglobulin G. , 2003, Vaccine.
[41] R K Jain,et al. Direct in vivo measurement of targeted binding in a human tumor xenograft. , 1997, Proceedings of the National Academy of Sciences of the United States of America.